Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Total revenues	$ 138,590	$ 104,754	$ 69,056
Americas
Disaggregation of Revenue [Line Items]
Total revenues	17,000	23,481	24,352
EMEA
Disaggregation of Revenue [Line Items]
Total revenues	56,540	20,187	19,257
APAC
Disaggregation of Revenue [Line Items]
Total revenues	65,050	61,086	25,447
Product revenue
Disaggregation of Revenue [Line Items]
Total revenues	116,676	70,657	30,220
Research and development revenue
Disaggregation of Revenue [Line Items]
Total revenues	21,914	34,097	38,836
Performance Enzymes
Disaggregation of Revenue [Line Items]
Total revenues	126,612	90,515	48,106
Performance Enzymes | Americas
Disaggregation of Revenue [Line Items]
Total revenues	12,089	16,114	11,111
Performance Enzymes | EMEA
Disaggregation of Revenue [Line Items]
Total revenues	49,473	13,315	11,548
Performance Enzymes | APAC
Disaggregation of Revenue [Line Items]
Total revenues	65,050	61,086	25,447
Performance Enzymes | Product revenue
Disaggregation of Revenue [Line Items]
Total revenues	116,676	70,657	30,220
Performance Enzymes | Research and development revenue
Disaggregation of Revenue [Line Items]
Total revenues	9,936	19,858	17,886
Novel Biotherapeutics
Disaggregation of Revenue [Line Items]
Total revenues	11,978	14,239	20,950
Novel Biotherapeutics | Americas
Disaggregation of Revenue [Line Items]
Total revenues	4,911	7,367	13,241
Novel Biotherapeutics | EMEA
Disaggregation of Revenue [Line Items]
Total revenues	7,067	6,872	7,709
Novel Biotherapeutics | APAC
Disaggregation of Revenue [Line Items]
Total revenues	0	0	0
Novel Biotherapeutics | Product revenue
Disaggregation of Revenue [Line Items]
Total revenues	0	0	0
Novel Biotherapeutics | Research and development revenue
Disaggregation of Revenue [Line Items]
Total revenues	$ 11,978	$ 14,239	$ 20,950